Methodologies for Population Pharmacokinetic Modeling of Target-Site Drug Exposure: A Narrative Review of Current Strategies [0.03%]
基于作用位点暴露的群体药代动力学模型方法学进展：现状与展望
Michelle Mehciz,Pascale C S Rietveld,Birgit C P Koch et al.
Michelle Mehciz et al.
Model-informed precision dosing (MIPD) is increasingly used to guide drug dosing based on population pharmacokinetic (popPK) models developed mainly using plasma concentration data. However, plasma levels may not always correlate well with ...
β-Lactam Antibiotics in Obese Adults: A Review of Population Pharmacokinetic Analyses [0.03%]
用于肥胖成年人的β-内酰胺类抗生素：人群药代动力学分析综述
Guiva Annane,Benoît Crevier,Anis Ouyahia et al.
Guiva Annane et al.
Obesity is becoming more prevalent, and it significantly alters drug pharmacokinetics (PK), potentially impacting the efficacy and safety of β-lactam antibiotics. Population pharmacokinetic (popPK) modeling plays a crucial role in optimizi...
A Mycophenolate Pharmacokinetic Study with New Insights into Enterohepatic Recirculation in Kidney Transplant Recipients [0.03%]
他克莫司合并霉酚酸治疗的肾移植患者霉酚酸酯药代动力学研究及肠道肝循环的新认识
Moataz E Mohamed,Abdelrahman Saqr,Guillaume Onyeaghala et al.
Moataz E Mohamed et al.
Background: Mycophenolic acid (MPA) has complex pharmacokinetics in part due to enterohepatic recirculation (EHR). A deeper understanding of MPA pharmacokinetics and specifically how EHR and patterns of EHR affect exposur...
Use of a Cystatin C-Based GFR Equation in a Population Pharmacokinetic Model of Methotrexate Clearance in Adult Patients with Lymphoma [0.03%]
基于胱抑素C的GFR方程在成人淋巴瘤患者甲氨蝶呤清除群体药代动力学模型中的应用
Zachary L Taylor,Erin F Barreto,Kristin C Cole et al.
Zachary L Taylor et al.
Background: High-dose methotrexate (HDMTX) is a key treatment for lymphoma with central nervous system involvement. Whether incorporating cystatin C into glomerular filtration rate estimation improves methotrexate (MTX) c...
Accurate Estimation of Glomerular Filtration Rate in Critically Ill Infants and Children Using a Iohexol Population Pharmacokinetic Modeling Approach [0.03%]
使用碘海醇人群药代动力学模型法准确估算重症婴儿和儿童的肾小球滤过率
Evelyn Dhont,Alexandre Destere,Alexandre Gerard et al.
Evelyn Dhont et al.
Background and objective: Accurate assessment of the glomerular filtration rate (GFR) is crucial in critically ill children, yet standard estimation formulas (eGFR) perform poorly, especially in the youngest. Iohexol plas...
Pharmacokinetics and Safety of a Single Dose of Brensocatib in Participants with Hepatic Impairment and Matched Participants with Normal Hepatic Functions [0.03%]
布罗索坦ib单次给药在肝功能不全受试者和肝功能正常匹配受试者中的药代动力学和安全性研究
Helen Usansky,Sam Au Yeung,Sherry Li et al.
Helen Usansky et al.
Aim: Brensocatib is an oral, competitive, and reversible dipeptidyl peptidase 1 (DPP1) inhibitor in development for the treatment of neutrophil-mediated diseases. Brensocatib is a substrate of CYP3A, P-glycoprotein, and b...
Therapeutic Drug Monitoring for Improving Tuberculosis Treatment Outcomes: A Scoping Review of Clinical Studies [0.03%]
改善结核病治疗效果的药物治疗监测：临床研究综述
Aisya Rezki Noeriman,Sumarheni Sumarheni,Aliya Nur Hasanah et al.
Aisya Rezki Noeriman et al.
Background: Therapeutic drug monitoring (TDM) is a tool used for dose optimization to achieve therapeutic concentrations associated with improved outcomes. However, evidence supporting its benefits for tuberculosis (TB) t...
The Effect of Taking Cabozantinib with a Light Breakfast: A Randomized Crossover Pharmacokinetic Study (SKIPPY 1) [0.03%]
一份轻量级早餐对卡博替尼药代动力学影响的随机交叉研究（SKIPPY 1）
Amy Rieborn,Niels A D Guchelaar,Teun van Gelder et al.
Amy Rieborn et al.
Background and objective: Cabozantinib is a tyrosine kinase inhibitor approved for the treatment of metastatic renal cell carcinoma. The current patient-unfriendly advice to ingest cabozantinib in a fasted state is based ...
Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness [0.03%]
基于模型的替尔奥马bsc替代给药策略以改善成本效益性
Yang Wang,Laura H Bukkems,Rob Ter Heine et al.
Yang Wang et al.
Background: The increasing use of the immune checkpoint inhibitor nivolumab places a significant financial burden on healthcare systems, contributes to environmental concerns, and strains hospital capacities. The nivoluma...
Correction: Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10‑Monohydroxy Derivative to Inform Dosing in Children with Obesity [0.03%]
Correction: 卡马西平及其活性代谢产物单羟基衍生物的群体药代动力学模型，用于指导肥胖儿童给药剂量的研究
Jaydeep Sinha,Kanecia Zimmerman,Stephen J Balevic et al.
Jaydeep Sinha et al.
Published Erratum
Clinical pharmacokinetics. 2026 Jan 6. DOI:10.1007/s40262-025-01613-1 2026